Progression of X-linked Adrenoleukodystrophy Under Interferon-beta Therapy

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 1997 Mar 1

PMID 9061569

Citations 5

Authors

G C Korenke

H J Christen

B Kruse

D H Hunneman

F Hanefeld

Affiliations

Soon will be listed here.

Abstract

The cerebral phenotype of X-linked adrenoleukodystrophy (ALD) is a rapidly progressive neurodegenerative disorder characterized by a cerebral inflammatory response and elevated very long-chain fatty acids (VLCFA). Interferon-beta (INFB) is known to suppress the synthesis of tumour necrosis factor alpha and interferon-gamma, which have been reported to be elevated in the margin of the areas of demyelination in ALD brains. We report on treatment with interferon-beta in 8 patients with cerebral ALD, who additionally received glycerol trioleate/glycerol trierucate. INFB-1 a (Rebif, Serono, Switzerland) was given subcutaneously once a week, 3 million units for the first 3 months and 6 million units for the next 9 months. All patients showed an unimpeded progression of neurological symptoms during INFB therapy. Therapy was stopped within 6 months in 4 patients because of the fast neurological deterioration with loss of walking. In all patients the MRI demonstrated a progression of demyelination with a qualitatively unchanged gadolinium enhancement. Further studies are needed to elucidate the pathomechanism of demyelination in ALD in order to find an effective therapy for cerebral ALD patients.

Citing Articles

Saturated very long-chain fatty acids regulate macrophage plasticity and invasiveness.

Zierfuss B, Buda A, Villoria-Gonzalez A, Logist M, Fabjan J, Parzer P J Neuroinflammation. 2022; 19(1):305.

PMID: 36528616 PMC: 9759912. DOI: 10.1186/s12974-022-02664-y.

B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy.

Rosewich H, Nessler S, Bruck W, Gartner J Ther Adv Neurol Disord. 2019; 12:1756286419868133.

PMID: 31452685 PMC: 6696829. DOI: 10.1177/1756286419868133.

Modeling and rescue of defective blood-brain barrier function of induced brain microvascular endothelial cells from childhood cerebral adrenoleukodystrophy patients.

Lee C, Seo H, Armien A, Bates F, Tolar J, Azarin S Fluids Barriers CNS. 2018; 15(1):9.

PMID: 29615068 PMC: 5883398. DOI: 10.1186/s12987-018-0094-5.

Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy.

Berger J, Pujol A, Aubourg P, Forss-Petter S Brain Pathol. 2010; 20(4):845-56.

PMID: 20626746 PMC: 2967711. DOI: 10.1111/j.1750-3639.2010.00393.x.

Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

van Geel B, Assies J, Haverkort E, Koelman J, Verbeeten Jr B, Wanders R J Neurol Neurosurg Psychiatry. 1999; 67(3):290-9.

PMID: 10449548 PMC: 1736534. DOI: 10.1136/jnnp.67.3.290.

References

Powers J, Liu Y, Moser A, Moser H . The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol. 1992; 51(6):630-43. DOI: 10.1097/00005072-199211000-00007. View

Korenke G, Hunneman D, Kohler J, Stockler S, Landmark K, Hanefeld F . Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters. Eur J Pediatr. 1995; 154(1):64-70. DOI: 10.1007/BF01972976. View

Stumpf D, Hayward A, Haas R, Frost M, Schaumburg H . Adrenoleukodystrophy. Failure of immunosuppression to prevent neurological progression. Arch Neurol. 1981; 38(1):48-9. DOI: 10.1001/archneur.1981.00510010074014. View

Jacobs L, Cookfair D, Rudick R, Herndon R, Richert J, Salazar A . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996; 39(3):285-94. DOI: 10.1002/ana.410390304. View

Cappa M, Bertini E, del Balzo P, Cambiaso P, di Biase A, Salvati S . High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry. 1994; 57 Suppl:69-70; discussion 71. PMC: 1016731. DOI: 10.1136/jnnp.57.suppl.69. View

Korenke G, Christen H, Hunneman D, Hanefeld F . Failure of beta interferon therapy in X-linked adrenoleukodystrophy. Eur J Pediatr. 1996; 155(9):833. DOI: 10.1007/BF02002922. View

Loes D, Hite S, Moser H, Stillman A, Shapiro E, Lockman L . Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol. 1994; 15(9):1761-6. PMC: 8333737. View

Schaumburg H, Powers J, Raine C, Suzuki K, Richardson Jr E . Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol. 1975; 32(9):577-91. DOI: 10.1001/archneur.1975.00490510033001. View

. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993; 43(4):655-61. DOI: 10.1212/wnl.43.4.655. View

10.

Weinstock-Guttman B, Ransohoff R, Kinkel R, Rudick R . The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol. 1995; 37(1):7-15. DOI: 10.1002/ana.410370105. View

11.

Stone L, Frank J, Albert P, Bash C, Smith M, Maloni H . The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995; 37(5):611-9. DOI: 10.1002/ana.410370511. View

12.

Naidu S, Bresnan M, Griffin D, OToole S, Moser H . Childhood adrenoleukodystrophy. Failure of intensive immunosuppression to arrest neurologic progression. Arch Neurol. 1988; 45(8):846-8. DOI: 10.1001/archneur.1988.00520320032011. View

13.

Kumar A, ROSENBAUM A, Naidu S, Wener L, Citrin C, Lindenberg R . Adrenoleukodystrophy: correlating MR imaging with CT. Radiology. 1987; 165(2):497-504. DOI: 10.1148/radiology.165.2.3659373. View

14.

Moser H, Moser A, Smith K, Bergin A, Borel J, Shankroff J . Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis. 1992; 15(4):645-64. DOI: 10.1007/BF01799621. View